So let's just stay on this question about MannKind (MNKD) for another post.
A couple days ago -- the big news was about the FDA approval of a new product for them --- which created the question from Sebtarta. To which I responded that "I don't know anything about them".
That quote is really larger than just about the one single company. I have often stated in this thread to stick to what you know and understand. To do otherwise is a tar pit trap. You buy based on something you've heard - or buy because something is going up and CNBC is talking about it... But you really have no GD idea what the larger picture is - competitors - revenue - growth potential - management... etc.
So this is TODAYS news on MannKind (MNKD) --- and bam! Down 4.5% from yesterday. When I'm trying to earn 4.5% or 5% in dividends (and get capital growth on top of that) I don't need to be down that much in one day. And these kinds of stocks are purely NEWS DRIVEN or event driven. UP DOWN UP DOWN... Personally... my stomach can't deal with that.
Now -- the stock could shoot to the moon.... and many people could make a killing on it. But you could also just as easily get killed. I don't want to invest in that kind of risk. I'd rather be like Albert and roll out my dividend calendar! LOL
Cut and pasted:
MannKind Corporation (NASDAQ:MNKD)’s inhaled insulin drug Afrezza won the USFDA approval on Friday, June 27 for type 1 and type 2 diabetes. Though it’s a positive for the biopharma company that doesn’t yet generate a revenue, there are some big concerns around potential commercialization of Afrezza. That’s the key reason JPMorgan’s biotechnology analyst Cory Kasimov still has a Neutral rating on the stock with $6 price target, reflecting about 40% downside potential.
|